

CIRUGÍA ESPAÑOLA

www.elsevier.es/cirugia



Original article

Predictors of Wound Infection in Elective Colorectal Surgery. Multicenter Observational Case–Control Study $^{\diamond}$



Doménico Fraccalvieri,^{a,*} Esther Kreisler Moreno,^a Blas Flor Lorente,^b Antonio Torres García,^c Alberto Muñoz Calero,^d Francisco Mateo Vallejo,^e Sebastiano Biondo^a

^a Servicio de Cirugía General, Hospital Universitario de Bellvitge, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universidad de Barcelona, Barcelona, Spain

^b Servicio de Cirugía General, Hospital Clínico Universitario de Valencia, Valencia, Spain

^c Servicio de Cirugía General, Hospital Clínico San Carlos, Madrid, Spain

^d Servicio de Cirugía General, Hospital Universitario Gregorio Marañon, Madrid, Spain

^e Servicio de Cirugía General, Hospital General de Jerez, Jerez, Spain

ARTICLE INFO

Article history: Received 12 July 2013 Accepted 29 July 2013 Available online 12 July 2014

Keywords: Colorectal surgery Surgical wound infection Organ space infection Vicryl Plus

ABSTRACT

Introduction: The aim of this study is to evaluate the usefulness of Vicryl Plus[®] suture in reducing the rate of postoperative wound infection in elective colorectal surgery.

Methods: A prospective case–control multicenter study with 480 patients undergoing elective colorectal surgery was performed between 2006 and 2007. Patients were divided in 2 groups of equal sample size: group 1, closure of the abdominal wall using Vicryl Plus[®] and group 2 where PDS II[®] was used. The study involved 5 hospitals in the Spanish State. Wound infection was classified into superficial and deep. All patients diagnosed of wound infection during the hospital stay and up to 30 days after discharge were studied. For the statistical analysis Chi-square test and Fisher exact were used for bivariate analysis and logistic regression model for multivariate analysis.

Results: Wound infection rates were significantly lower in group 1: 14.6 vs 29.2. Multivariate analysis showed that risk of wound infection was higher in patients with cancer, lung disease, anemia, operative time greater than 2 h, lack of second dose intra-operative prophylactic antibiotic and laparotomy closure with PDS suture II[®].

Conclusions: The use of suture coated with triclosan can be an effective prophylactic tool in reducing wound infection rate in patients undergoing elective colorectal surgery.

© 2013 AEC. Published by Elsevier España, S.L.U. All rights reserved.

* Corresponding author.

E-mail address: dofrac@yahoo.es (D. Fraccalvieri).

2173-5077/\$ – see front matter © 2013 AEC. Published by Elsevier España, S.L.U. All rights reserved.

^{*} Please cite this article as: Fraccalvieri D, Kreisler Moreno E, Flor Lorente B, Torres García A, Muñoz Calero A, Mateo Vallejo F, et al. Factores predictivos de infección de herida en cirugía colorrectal. Estudio observacional multicéntrico de casos y controles. Cir Esp. 2014;92:478–484.

Factores predictivos de infección de herida en cirugía colorrectal. Estudio observacional multicéntrico de casos y controles

RESUMEN

Introducción: El objetivo de este estudio es evaluar la utilidad del material de sutura Vicryl Plus[®] en reducir la tasa de infección de herida postoperatoria en cirugía colorrectal electiva. *Método:* Estudio de casos y controles prospectivo multicéntrico sobre 480 pacientes intervenidos de cirugía colorrectal electiva entre el 2006 y 2007, divididos en 2 grupos de igual tamaño muestral, sometidos a cierre de pared abdominal mediante uso de Vicryl Plus[®] (grupo 1) y PDS II[®] (grupo 2). En el estudio participaron 5 centros hospitalarios del Estado Español. La infección de herida fue clasificada en superficial y profunda. Fueron incluidos todos los pacientes diagnosticados de infección de herida durante la estancia hospitalaria y hasta 30 días después del alta. Para el estudio estadístico fueron utilizados el test del Chi-cuadrado y el exacto de Fisher para el análisis bivariante y el modelo de regresión logística para el análisis multivariante.

Resultados: La tasa de infección de herida observada fue significativamente inferior en el grupo 1: 14,6 frente al 29,2 del grupo 2. Según el estudio multivariante, el riesgo de infección de herida es superior en los pacientes con neoplasia, enfermedad pulmonar, anemia, tiempo operatorio superior a 2 h, falta de segunda dosis profiláctica intraoperatoria y cierre de laparotomía con sutura de PDS II[®].

Conclusiones: El uso de material de sutura recubierto de triclosan puede ser una herramienta profiláctica eficaz para disminuir la tasa de infección de herida operatoria en los pacientes intervenidos mediante cirugía colorrectal electiva.

Method

© 2013 AEC. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

Introduction

Palabras clave:

Vicryl Plus

Cirugía colorrectal

Infección herida quirúrgica

Infección de órgano y espacio

Wound infection is the most common complication among patients undergoing elective colorectal surgery; it has a significant impact on morbidity and health care costs. Incidence varies between 5% and 40%; the main reason for this discrepancy depends on whether infections occurring after hospital discharge are included or not.^{1–5} The etiology of surgical infection is multifactorial and results from the interaction of many variables related to the patient, germ, intervention and hospitalization. Diabetes, malnutrition, immunosuppression, obesity, anemia and transfusion have been the main risk factors studied.^{6–20}

Other causes have been related to the surgical intervention, such as hypothermia, hypoxia, surgery type, bowel preparation, procedure duration, use of wall protection methods, antibiotic prophylaxis and the time of administration.⁶⁻¹³ In recent years, there has been growing interest in how suture materials influence wound infection development. The hypothesis is that suture materials favor bacterial colonization, reducing local and systemic therapeutic measure effectiveness.⁸ Vicryl Plus[®] is a suture thread coated with triclosan to fight Gram-positive and Gram-negative bacteria, thus reducing the potential for infection initiation and propagation; in vitro studies and animal models have demonstrated its effectiveness.14-19 However, there is less scientific evidence of its efficacy from a clinical point of view. This study has aimed mainly to evaluate the possible clinical benefit of Vicryl Plus[®] in reducing wound infection rates and decreasing hospital stay for patients with infected wounds from elective colorectal surgery laparotomy closures.

In order to assess the actual benefit of a suture material with antiseptic properties on laparotomy closures, a prospective case-control study was conducted including patients who underwent surgery for elective colorectal disease in 2006-2007. The study group comprised 240 consecutive patients who underwent abdominal wall closure with Vicryl Plus[®] (Triclosan, Ethicon Deutschland, Norderstedt, Germany coated antibacterial polyglactin 910), whereas the control group comprised 240 patients who underwent laparotomy closure with conventional PDSII suture[®] (Polydioxanone, Ethicon Deutschland, Norderstedt, Germany). Control patients were selected retrospectively with the same inclusion and exclusion criteria of the studied group. All surgical procedures included were classified as clean-contaminated surgery. The study excluded patients with emergency colorectal resection, colorectal disease with multivisceral resection, and contaminated colorectal surgery cases. Wound infection was defined as spontaneous drainage of purulent material from the wound or from the surgeon's deliberate revision and positive culture of drained serous fluid. Infections were classified as superficial (skin and subcutaneous tissue), and deep (fascia and muscle tissue). All wound infection cases diagnosed during hospital stays were included, and those up to 30 days after discharge, diagnosed during ambulatory follow-up. Patients were classified based on malignant etiology (neoplasia) and benign etiology (diverticular and inflammatory bowel disease). Different variables considered as potential risk factors for surgical infection were studied by bivariate analysis: age over 70 years, malignant etiology, diabetes, chronic renal insufficiency (serum creatinine>1.2 mg/dL), hypoalbuminemia (serum albumin<3.5 g/dL), obesity (BMI>30 kg/m²), anemia (hemoglobin<12 g/dL), concomitant steroid therapy, and chronic lung disease. Evaluated surgical variables were: surgery duration longer than 2 h, administration of a second dose of intraoperative antibiotic prophylaxis, and using Vicryl Plus[®] for laparotomy closure.

Statistical Analysis

For the categorical variable study, Chi-square and Fisher's exact tests were used, based on application conditions. The Mann–Whitney U test was used to analyze quantitative variables. Odds ratios were used to measure associations. The multivariate logistic regression method and the Hosmer and Lomeshow test were applied to study the relationship between dependent and independent variables.

Results

Study Group Characteristics

Characteristics of patients in the 2 study groups are reported in Table 1. Average patient age for the case group was 64.2 years (18-86 year range), and 65 years for the control group (20-89 year range). Not all variables considered were homogeneous in the 2 groups. Differences were found regarding etiology, anemia, obesity, surgery duration, and administration of a second antibiotic dose at 3 h. after surgery. Neoplasm was the most common etiology in both groups: 92.1% (221/240) for the case group, and 85.4% (205/240) for the control group (P=.021). 26.7% (64/240) of patients in the Vicryl $Plus^{\scriptstyle{(B)}}$ group had anemia, compared to 9.2% (22/240) of the PDS II[®] group (P<.001). A BMI greater than 30 kg/m² was observed in 3.8% (9/ 240) of patients in the case group, and 12.5% (30/240) of patients in the control group (P<.001). Surgery duration was greater than 2 h for 77.5% (186/240), and 99.2% (238/240) of patients, respectively (P<.001). All patients received antibiotic prophylaxis during induction of anesthesia; 75.4% (181/240) of cases in the Vicryl Plus [®] group, and 85.8% (206/240) of cases in the PDSII[®] group, received a second antibiotic dose at 3 h. after surgery (P=.004). Abdominal wall protection was applied during each surgical procedure.

Wound Infection Risk Factors

The bivariate study on different variables showed that the wound infection rate was significantly higher in cancer patients and chronic lung disease patients, if the surgery exceeded 2 h, in the event that no second antibiotic dose was administered at 3 h after surgery, and for laparotomy closures with conventional suture (PDS II[®]) (Table 2).

The multivariate analysis of the variables identified as potential surgical infection risk factors, and the non-homogeneous variables resulting from comparing the 2 groups, showed that the wound infection risk was 2.95 times higher in cancer patients, 2.97 times higher in chronic obstructive pulmonary disease patients, 2.33 times higher in anemia patients, 4.76 times higher if surgery exceeded 3 h, 3.02 times higher if no second antibiotic dose was administered during surgery, and 1.85 times with conventional suture compared to Vicryl Plus[®] (Table 3).

Main Results

The overall wound infection rate after wall closure with Vicryl Plus[®] was significantly lower compared to closure with PDS II1. Eleven cases of infection (31.4%) were diagnosed after hospital discharge.

Patients who suffered wound infections had longer hospital stays than patients who did not: 21.2 compared to 9.7 days (P<.001). However, for cases of wound infection, the average stay of patients in the Vicryl Plus[®] group was significantly lower than for those in the PDS II[®] group (Table 4).

Discussion

In this study, the authors wanted to evaluate the impact of several risk factors for wound infection in elective colorectal surgery, with special emphasis on the influence of the suture material used for laparotomy closure. Short-medium absorption suture such as Vicryl Plus[®] was used, rather than long-absorption monofilament suture, due to the fact that it was the only available triclosan coated suture at the time of the study.

Various research projects have studied triclosan's antibacterial activity, in vitro and with animals.¹⁵⁻¹⁹ Other studies tested biocompatibility and safety of triclosan-coated 910 Polyglactil for clinical use.^{14,21} Ford et al. demonstrated the efficacy of Vicryl Plus® in pediatric patients with a randomized clinical trial.²² A systematic review published in 2012 showed no significant differences between Vicryl[®] with and without triclosan, considering a large sample of 836 patients derived from a pooled analysis of 7 randomized studies.²³ Moreover, a subsequent meta-analysis with greater statistical power, including 17 randomized studies, showed a significant benefit from triclosan-coated sutures in clean-contaminated abdominal surgery and in adult patients.²⁴ Nakamura et al. have recently published a randomized prospective study on the effects of Vicryl Plus® on elective colorectal surgery, demonstrating a significant decrease in the rate of surgical infection compared to patients where Vicryl[®] without triclosan was used, 4.3% compared to 9.3%.²⁵

One of the limitations of this study is related to the characteristics of the patients. Some of the variables were significantly different for the comparative analysis of the 2 groups. These differences are probably due to the fact that they are 2 consecutive series of patients. To reduce the influence of this bias on study results, a multivariate analysis was performed to determine the influence of variables potentially involved in surgical site infection.

In our experience, patients treated with Vicryl Plus[®] had a 14.6% wound infection rate, significantly lower compared to 29.2% for the group treated with PDSII[®]. In a 2009 prospective study comparing Vicryl Plus[®] to PDSII[®], Justinger et al. reported a significantly lower wound infection rate using Vicryl Plus[®]: 4.9% compared to 10.8%.²⁶ However, the study

Female8635.89037.5Diagnosis	Variables	Vicryl Plus		PDS II		P-value
Male 154 64.2 150 62.5 Female 36 35.8 30 37.5 Diagnosis Diagnosis Benign 19 7.9 35 14.6 Corticosteroids No 226 94.2 224 93.3 Pres 14 5.8 16 6.7 No 159 66.3 133 55.4 No 159 66.3 133 55.4 Diabets		No.	%	No.	%	
Female8635.89037.5Diagnosis	Gender					
Name Name <t< td=""><td>Male</td><td>154</td><td>64.2</td><td>150</td><td>62.5</td><td>.705</td></t<>	Male	154	64.2	150	62.5	.705
Malignant22192.120585.4Benign197.935146CorticosteroidsNo22694.222499.3Yes145.8166.7HypertensionNo15966.313355.4Yes8133.810744.6DiabetesNo20485.020384.6Yes3615.03715.4Kidney failureNo22492.522593.8Yes187.5156.3Yes187.5156.3No22292.522593.8Yes6426.7229.2ObesityNo23196.321087.5<	Female	86	35.8	90	37.5	
Benign197.93514.6CorticostervidsNo22694.222493.3.No15966.313355.4Hypertension33.810744.6Stoketes33.810744.6No20485.020384.6Yes3610.03715.4StoketesNo20485.020384.6Yes36No23497.5.23497.5Yes62.56No22292.522593.8No17673.321890.8No23196.3.012.5No23196.3.0.12.5No23196.3.0.0	Diagnosis					
Scrittosteroids No 226 94.2 224 93.3 Yes 14 5.8 16 6.7 typertension No 159 66.3 133 55.4 Yes 81 33.8 107 44.6 Diabets No 204 85.0 203 84.6 Yes 36 15.0 37 15.4 No 234 97.5 234 97.5 1 Yes 6 2.5 6 2.5 1 Stappalburninemia No 176 73.3 218 90.8 <						.021
No 226 94.2 224 93.3 Yes 14 5.8 16 6.7 Hyperension No 159 66.3 133 55.4 Yes 81 33.8 107 44.6 Diabetes No 204 85.0 203 84.6 Ves 36 15.0 37 15.4 Kiney failure No 234 97.5 234 97.5 1. Hypollbuminemia .	Benign	19	7.9	35	14.6	
Yes145.8166.7Aypertension	Corticosteroids					
Appertension No 159 66.3 133 55.4 Yes 81 33.8 107 44.6 Diabetes No 204 85.0 203 84.6 Yes 36 15.0 37 15.4 Cidney failure No 234 97.5 234 97.5 1 Yes 6 2.5 6 2.5 Syoalburninemia No 222 92.5 225 93.8 Yes 18 7.5 15 6.3 Yes 64 26.7 22 9.2 No 231 96.3 210	No	226	94.2	224	93.3	.706
No 159 66.3 133 55.4 Yes 81 33.8 107 44.6 Diabetes No 204 85.0 203 84.6 Yes 36 15.0 37 15.4 Kidney failure No 234 97.5 234 97.5 1. Yes 6 2.5 6 2.5 Mo 234 97.5 15 6.3 Hypalbuminemia No 176 73.3 218 90.8 No 231 96.3 210 87.5 Stelerly Yes 9 3.8	Yes	14	5.8	16	6.7	
Yes8133.810744.6Diabetes 100 45.0 203 84.6 100 Yes36 150 203 84.6 100 Yes36 250 370 150 100 Cidney failure 100 234 97.5 234 97.5 100 No 234 97.5 234 97.5 100 100 Yes6 2.5 6 2.5 93.8 100 Hypoalbuminemia 100 105 100 100 100 No 222 92.5 225 93.8 100 Anemia 100 100 100 100 100 No 221 96.3 210 87.5 $<<<<100$ Yes 64 26.7 22 9.2 100 Destiy 100 100 87.5 $<<<100$ No 231 96.3 210 87.5 $<<<100$ Yes 134 55.8 144 60.0 $<<100$ 270 years 134 55.8 144 60.0 $<<100$ 270 years 134 55.8 144 60.0 $<<100$ 270 years 134 55.8 144 60.0 $<<100$ 200 years 134 55.8 144 60.0 <100 270 years 134 55.8 144 60.0 <100 200 years 25 20.4 37 36.6 <100 <t< td=""><td>-Typertension</td><td></td><td></td><td></td><td></td><td></td></t<>	-Typertension					
No 204 85.0 203 84.6 Yes 36 15.0 37 15.4 Cidney failure No 234 97.5 234 97.5 1. Yes 6 2.5 6 2.5 Hypalbuminemia No 222 92.5 225 93.8 Yes 18 7.5 15 6.3 Anemia No 176 73.3 218 90.8 No 176 73.3 210 87.5 Yes 9 3.8 30 12.5 Yes 9 3.8	No	159	66.3	133	55.4	.015
No20485.020384.6Yes3615.03715.4Kidney failureNo23497.523497.51.Yes62.562.5HypoalbuminemiaNo22292.522593.8Yes187.5156.3AnemiaNo17673.321890.8Yes6426.7229.2ObesityNo23196.321087.5Yes93.83012.5Stderly< 70 years	Yes	81	33.8	107	44.6	
Yes3615.03715.4Stdney failure No23497.523497.51.Yes62.562.51.Hypoalbuminemia No22292.522593.8.No22292.51.56.3.Anemia No17673.321890.8.No17673.321890.8.Yes6426.7229.2.Desity No23196.321087.5.No23196.321087.5.Yes93.83012.5.Carley < 70 years	Diabetes					
Kidney failureNo23497.523497.51.Yes62.562.59.8.Hypoalbuminemia7.5156.3.No22292.522593.8.Yes187.5156.3.Anemia7.52229.2No17673.321890.8.Yes6426.7229.2.Desity723196.321087.5.No23196.321087.5Yes93.83012.5Elderly70 years13455.814460.0.270 years13455.814460.0270 years2510.43715.4Surgery duration252.52.8Less than 2 h.5422.52.8Nore than 2 h18677.523899.2	No	204	85.0	203	84.6	.899
No23497.523497.51.Yes62.562.59Hypoalbuminemia	Yes	36	15.0	37	15.4	
Yes62.562.5HypalbuminemiaNo22292.522593.8.Yes187.5156.3.AmeniaNo17673.321890.8<.	Kidney failure					
HypadbuminemiaNo22292.522593.8Yes187.5156.3AnemiaNo17673.321890.8Yes6426.7229.2DesityNo23196.321087.5Yes93.83012.5ColoredYes13455.814460.0270 years13644.29640.0ang diseaseNo21589.620384.6Yes2510.43715.4Sargery durationLess than 2 hNo than 2 hNoNoSargery durationNoNo	No	234	97.5	234	97.5	1.000
No22292.522593.8.Yes187.5156.3Anemia 7.5 156.3No17673.321890.8Yes6426.7229.2Obesity 7.5 229.2 7.5 No23196.321087.5 $<.5$ Yes93.83012.5 7.5 $<.5$ Obesity 70 years13455.814460.0 $<.5$ Stderly $<.70$ years10644.29640.0 $<.5$ Stderly $<.70$ years10644.29640.0 $<.5$ Stagese $.5.8$ 14460.0 $<.5$ $<.5$ $<.5$ No21589.620384.6 $<.5$ $<.5$ Stargery duration $.54$ 22.52 $.8$ $<.5$ Less than 2 h.5422.52 $.8$ $<.5$ Wore than 2 h16677.523899.2 $<.5$	Yes	6	2.5	6	2.5	
Yes187.5156.3AnemiaNo17673.321890.8<.	Hypoalbuminemia					
AnemiaNo17673.321890.8<No17673.321890.8<						.588
No17673.321890.8<Yes6426.7229.29.2DesityNo23196.321087.5<	Yes	18	7.5	15	6.3	
Yes 64 26.7 22 9.2 DesityNo 231 96.3 210 87.5 $<.$ No 231 96.3 210 87.5 $<.$ Yes 9 3.8 30 12.5 $<.$ Ederly $< 70 years13455.814460.0<.\geq 70 years10644.29640.0<.ang diseaseNo21589.620384.6<.Yes2510.43715.4<$	Anemia					
Desity No23196.321087.5<.Yes93.83012.5.Clderly $3.83012.5.< 70 years13455.814460.0.\geq 70 years10644.29640.0.ung diseaseNo21589.620384.6.Yes2510.43715.4.Surgery durationLess than 2 h.5422.52.8<.$						<.001
No23196.321087.5<.Yes93.83012.5Elderly $< 70 years$	Yes	64	26.7	22	9.2	
Yes93.83012.5Stderly < 70 years13455.814460.0. ≥ 70 years10644.29640.0. ≥ 70 years10644.29640.0.sung disease						
Elderly< 70 years						<.001
<70 years13455.814460.0. ≥70 years10644.29640.0ung diseaseNo21589.620384.6Yes2510.43715.4Surgery durationLess than 2 h.5422.52More than 2 h18677.523899.2	Yes	9	3.8	30	12.5	
≥70 years 106 44.2 96 40.0						
Lung disease No 215 89.6 203 84.6 . Yes 25 10.4 37 15.4 . Surgery duration Less than 2 h. 54 22.5 2 .8 <.						.355
No 215 89.6 203 84.6 . Yes 25 10.4 37 15.4 . Surgery duration Less than 2 h. 54 22.5 2 .8 <. More than 2 h 186 77.5 238 99.2 .8 .	\geq 70 years	106	44.2	96	40.0	
Yes 25 10.4 37 15.4 Surgery duration						
Surgery duration 22.5 2 .8 <. Less than 2 h. 54 22.5 2 .8 <.						.102
Less than 2 h. 54 22.5 2 .8 <. More than 2 h 186 77.5 238 99.2	Yes	25	10.4	37	15.4	
More than 2 h 186 77.5 238 99.2						
						<.001
2nd antibiotic dose	More than 2 h	186	77.5	238	99.2	
No 60 25.0 34 14.2 <. Yes 180 75.0 206 85.8						<.001

included non-homogeneous patients due to the inclusion of different procedures, surgery contamination degree and surgical setting: hepatobiliopancreatic, intestinal, colorectal, vascular surgeries, as well as elective and emergency surgeries. In this study, the derivative impact of using Vicryl Plus[®] was evaluated, specifically in elective colorectal surgery on a series of 240 consecutive patients prospectively included. In order to increase the significance and consistency of the results, a control sample of patients was considered; they were included based on the same patient inclusion criteria in the group of interest; patients in the control group were treated with laparotomy closure using PDSII[®], because it is a very commonly used suture and conventionally used by surgeons belonging to the group of authors.

Eleven wound infection cases were diagnosed after hospital discharge. According to the results of a study by Smith et al., 49% of the wound infections in the patients included were diagnosed after discharge.⁴ The reason for the lack of consistency in the results in the literature may lie in the different system used to record wound infections; probably, the series with higher infection rates also include cases observed after hospital discharge.

In this study, the bivariate analysis showed that using Vicryl Plus[®] produced a significant reduction in wound infections, with a 14.6[%] rate, compared to 29.2% when using PDSII[®].

However, the risk of infection was also found to be associated with other factors such as cancer, chronic

Table 2 – Variables Relate	od to Wound Infostion			
Variable	No. of patients	Infection cases	%	P^*
Gender	No. of patients	infection cases	70	1
Male	304	65	21.4	.731
Female	176	40	22.7	., 51
Diagnosis				
Malignant	426	87	20.4	.031
Benign	54	18	33.3	.001
Corticosteroids				
No	450	96	21.3	.266
Yes	30	9	30.0	.200
		-		
Hypertension No	292	61	20.9	.515
Yes	188	44	23.4	.515
	100		23.1	
Diabetes	407	05	00.0	045
No	407 73	85 20	20.9 27.4	.215
Yes	73	20	27.4	
Kidney failure				
No	468	103	22.0	1.000
Yes	12	2	16.7	
Hypoalbuminemia				
No	447	96	21.5	.437
Yes	33	9	27.3	
Anemia				
No	394	83	21.1	.359
Yes	86	22	25.6	
Obesity				
No	441	95	21.5	.553
Yes	39	10	25.6	
Elderly				
<70 years	278	60	21.6	.856
\geq 70 years	202	45	22.3	
Lung disease				
No	418	79	18.9	<.001
Yes	62	26	41.9	(.001
Surgery duration Less than 2 h	56	4	7.1	.005
More than 2 h	424	4 101	23.8	.005
	12 1	101	23.0	
2nd antibiotic dose	014		16.4	000
No	214	35	16.4	.009
Yes	266	70	26.3	
Use of Vicryl Plus®				
No	240	70	29.2	<.001
Yes	240	35	14.6	


Table 3 – Multivariate Analysis: Factors Related to Surgical Infection.					
Risk factors	RO	RO 95 CI Min	RO 95 CI Max	Р	
Malignant etiology	2.955	1.495	5.843	.002	
Lung disease	2.976	1.644	5.390	.000	
Anemia	2.336	1.224	4.458	.010	
Surgery duration >2 h	4.768	1.506	15.093	.008	
2nd antibiotic dose	3.023	1.452	6.291	.003	
No Vicryl Plus®	1.853	1.106	3.104	.019	

pulmonary disease, surgery duration exceeding 2 h, and no administration of a second prophylactic antibiotic dose at 3 h. after surgery. For that reason, and because of the incomplete homogeneity of the 2 study groups, we applied a multivariate analysis; using Vicryl Plus proved to be a useful independent preventive measure; the risk of wound infection being 1.85 times higher in patients treated with polydioxanone suture. Other factors such as neoplastic etiology, chronic lung disease, anemia, surgery duration exceeding 2 h, and failure to administer an additional antibiotic prophylaxis dose at 3 h. after surgery were also associated with increased infection risk.

Table 4 – Results.			
Results	Vicryl Plus [®] %	PDS $II^{(\mathbb{R})}$ %	Р
Wound infection	14.6 (35/240)	29.2 (70/240)	<.001*
Superficial infection	13.8 (33/240)	27.1 (65/240)	<.001*
Deep infection	0.8 (2/240)	2.1 (5/240)	.450*
Evisceration	0.8 (2/240)	2.5 (6/240)	.285*
Stay (days)	13.7	23.5	.049

* Chi-square test and Fisher exact test.

** Mann–Whitney U test.



An important finding was the significant difference in hospital stay between patients with wound infections in the group treated with Vicryl Plus[®] compared to patients with infections in the control group: 13.7 and 23.5 days, respectively. This result suggests the possibility that the bacteriostatic effect of triclosan favors less colonization of the suture material by the microorganisms, therefore allowing for faster response to the medical treatment of the infection.

Given that this study is non-randomized, it is limited to highlighting the differences in results in terms of wound infection, comparing the use of Vicryl Plus[®] and PDSII[®].

The results shown indicate that using 910 Polyglactil with triclosan in clean-contaminated surgery, such as elective colorectal surgery, helps reduce abdominal wall infection rate, and consequently, hospital stays and healthcare costs. Additional randomized studies are needed to corroborate our findings (Fig. 1).

REFERENCES

- Leaper DJ, Van Goor H, Reilly J, Petrosillo N, Geiss HK, Torres AJ, et al. Surgical site infection – a European perspective of incidence and economic burden. Int Wound J. 2004;1:247–73.
- 2. Mallol M, Sabaté A, Kreisler E, Dalmau A, Camprubi I, Trenti L, et al. Incidence of surgical wound infection in elective colorectal surgery and its relationship with preoperative factors. Cir Esp. 2012;90:376–81.
- Poon JT, Law WL, Wong IW, Ching PT, Wong LM, Fan JK, et al. Impact of laparoscopic colorectal resection on surgical site infection. Ann Surg. 2009;249:77–81.

- 4. Smith RL, Bohl JK, McElearney ST, Friel CM, Barclay MM, Sawyer RG, et al. Wound infection after elective colorectal resection. Ann Surg. 2004;239:599–605.
- Tanner J, Khan D, Aplin C, Ball J, Thomas M, Bankart J. Post-discharge surveillance to identify colorectal surgical site infection rates and related costs. J Hosp Infect. 2009;72:243–50.
- Biondo S, Kreisler E, Fraccalvieri D, Basany EE, Codina-Cazador A, Ortiz H. Risk factors for surgical site infection after elective resection for rectal cancer. A multivariate analysis on 2,131 patients. Colorectal Dis. 2012;14:e95–102.
- Wick EC, Gibbs L, Indorf LA, Varma MG, García-Aguilar J. Implementation of quality measures to reduce surgical site infection in colorectal patients. Dis Colon Rectum. 2008;51:1004–9.
- Ortiz H, Biondo S, Ciga MA, Kreisler E, Oteiza F, Fraccalvieri D. Comparative study to determine the need for intraoperative colonic irrigation for primary anastomosis in left-sided colonic emergencies. Colorectal Dis. 2009:11:648–52.
- 9. Biondo S, Kreisler E, Millan M, Fraccalvieri D, Golda T, Frago R, et al. Impact of surgical specialization on emergency colorectal surgery outcomes. Arch Surg. 2010;145:79–86.
- Biondo S, Ortiz H, Lujan J, Codina-Cazador A, Espin E, García-Granero E, et al. Quality of mesorectum after laparoscopic resection for rectal cáncer – result of an audited teaching programme in Spain. Colorectal Dis. 2010;12:24–31.
- Kurz A, Sessler DI, Lenhardt. Perioperative normothermia to reduce the incidence of surgical wound infections and shorten hospitalization. Study of wound infections and temperature group. N Engl J Med. 1996;334:1209–15.
- 12. Belda FJ, Aguilera L, García de la Asunción J, Alberti J, Vicente R, Ferrándiz L, et al. Supplemental perioperative oxygen and the risk of surgical wound infection: a randomized controlled trial. JAMA. 2005;294:2035–42. 26.
- Nelson RL, Glenny AM, Song F. Antimicrobial prophylaxis for colorectal surgery. Cochrane Database Syst Rev. 2009;CD001181.
- 14. Barbolt TA. Chemistry and safety of triclosan, and its use as an antimicrobial coating on Coated VICRYL* Plus Antibacterial Suture (coated polyglactin 910 suture with triclosan). Surg Infect (Larchmt). 2002;3:S45–53 [Review].
- 15. Rothenburger S, Spangler D, Bhende S, Burkley D. In vitro antimicrobial evaluation of coated VICRYL* Plus antibacterial suture (coated polyglactin 910 with triclosan) using zone of inhibition assays. Surg Infect. 2002;1:79–87.
- Pratten J, Nazhat SN, Blaker JJ, Boccacini AR. In-vitro attachment of Staphylococcus epidermidis to surgical sutures with and with Ag-containing bioactive glass coating. J Biomater Appl. 2004;19:47–57.
- Storch ML, Rothenburger SJ, Jacinto G. Experimental efficacy study of coated Vicryl Plus antibacterial suture in guinea pigs challenged with Staphylococcus aureus. Surg Infect. 2004;5:281–8.
- 18. Gómez-Alonso A, Garcuía-Criado FJ, Parreño-Manchado FC, Garcuía-Sánchez JE, Garcuía-Sánchez E, Parreño-Manchado A, et al. Study of the efficacy of coated VICRYL Plus antibacterial suture (coated polyglactin 910 suture with triclosan) in two animal models of general surgery. J Infect. 2007;54:82–8.
- Marco F, Vallez R, Gonzalez P, Ortega L, de la Lama J, López-Duran L. Study of the efficacy of coated Vicryl plus antibacterial suture in an animal model of orthopedic surgery. Surg Infect (Larchmt). 2007;8:359–65.
- 20. Gilbert P, McBain AJ. Literature-based evaluation of the potential risks associated with impregnation of medical devices and implants with triclosan. Surg Infect (Larchmt). 2002;3:55–63.

- 21. Edmiston CE, Seabrook GR, Goheen MP, Krepel CJ, Johnson CP, Lewis BD, et al. Bacterial adherence to surgical sutures: can antibacterial coated sutures reduce the risk of microbial contamination? J Am Coll Surg. 2006;203:481–98.
- 22. Ford HR, Jones P, Gaines B, Reblock K, Simpkins DL. Intraoperative handing and wound healing: controlled clinical trial comparing coated VICRYL plus antibacterial suture (coated polyglactin 910 suture with triclosan) with coated Vicryl suture (coated polyglactin 910). Surg Infect (Larchmt). 2005;6:313–21.
- **23.** Chang WK, Srinivasa S, Morton R, Hill AG. Triclosanimpregnated suture to decrease surgical site infections:

systematic review and meta-analysis of randomized trials. Ann Surg. 2012;255:854–9.

- 24. Wang ZX, Jiang CP, Cao Y, Ding YT. Systematic review and mata-analysis of triclosan-coated sutures for the prevention of surgical-site infection. Br J Surg. 2013;100:465–73.
- 25. Nakamura T, Kashimura N, Noji T, Suzuki O, Ambo Y, Nakamura F, et al. Triclosan-coated suture reduce the incidence of wound infections and the costs after colorectal surgery: a randomized controlled trial. Surgery. 2013;153:576–83.
- Justinger C, Moussavian MR, Schlueter C, Kopp B, Kollmar O, Shilling MK. Antibacterial coating of abdominal closure sutures and wound infection. Surgery. 2009;145:330–4.